Clinical Trials
108 trialsNCT06233942 2026-06-05
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06242691 2026-06-05
MK-1200-002
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT06554795 2026-06-05
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Recruiting
NCT06710756 2026-06-05
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
Phase 1/2 Recruiting
NCT07205718 2026-06-05
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Takeda
Phase 1/2 Recruiting
NCT07223125 2026-06-05
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07359820 2026-06-05
ReFocus202
Elevar Therapeutics
Phase 2 Recruiting
NCT06480552 2026-06-04
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Recruiting
NCT06596473 2026-06-04
A Study of BG-C477 in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06756035 2026-06-04
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
Phase 1 Recruiting
NCT07362888 2026-06-04
First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
Adcendo ApS
Phase 1 Recruiting
NCT07395258 2026-06-04
A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Suspended
NCT07408258 2026-06-04
Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors
OncoC4, Inc.
Phase 1 Not yet recruiting
NCT05579366 2026-06-03
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT05981703 2026-06-03
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06585488 2026-06-03
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BeOne Medicines
Phase 1 Terminated
NCT06589596 2026-06-03
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07042100 2026-06-03
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
Sun Pharma Advanced Research Company Limited
Phase 1 Recruiting
NCT07077434 2026-06-03
A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
NCT07226349 2026-06-03
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07414836 2026-06-03
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07593144 2026-06-03
A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)
Foresight Therapeutics (Hefei) Co., Ltd.
Phase 1 Not yet recruiting
NCT07622225 2026-06-03
SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1/2 Not yet recruiting
NCT07622524 2026-06-03
A Phase I Study of CS5007 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1 Not yet recruiting
NCT07623707 2026-06-03
A Study of FG-B901 Monotherapy or Combination With Chemotherapy in Advanced or Metastatic Solid Tumors
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 1/2 Not yet recruiting
NCT07624864 2026-06-03
A Study to Evaluate the Safety, Tolerability, PK and Efficacy of Hemay5087 in Patients With Advanced Solid Tumors
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 1 Not yet recruiting
NCT04303858 2026-06-02
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT04981119 2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
NCT06031441 2026-06-02
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Recruiting
NCT06057038 2026-06-02
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
Genmab
Phase 1 Active not recruiting
NCT06815575 2026-06-02
A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.
Racura Oncology Ltd
Phase 1 Recruiting
NCT07387068 2026-06-02
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Genmab
Phase 1 Recruiting
NCT07584226 2026-06-02
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
Relay Therapeutics, Inc.
Phase 1 Recruiting
NCT07620041 2026-06-02
QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction
Qilu Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT05571969 2026-06-01
Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors
Allarity Therapeutics
Phase 1 Terminated
NCT06619587 2026-06-01
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Genentech, Inc.
Phase 1 Recruiting
NCT06833008 2026-06-01
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
Phase 1/2 Recruiting
NCT07196644 2026-06-01
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
AbbVie
Phase 2 Recruiting
NCT07524348 2026-06-01
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
Samsung Bioepis Co., Ltd.
Phase 1 Recruiting
NCT07612189 2026-06-01
A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors
NEOK Bio, Inc.
Phase 1 Recruiting
NCT07617493 2026-06-01
Evaluation of ICP-B208 in Patients With Advanced Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07617727 2026-06-01
A Phase I Study of JSKN021 in Advanced Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1 Not yet recruiting
NCT05886920 2026-05-29
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
D3 Bio (Wuxi) Co., Ltd
Phase 1/2 Active not recruiting
NCT06115642 2026-05-29
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1 Enrolling by invitation
NCT06235983 2026-05-29
A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT06598800 2026-05-29
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06625593 2026-05-29
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06660654 2026-05-29
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Daiichi Sankyo
Phase 2 Active not recruiting
NCT07615413 2026-05-29
Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT07615660 2026-05-29
CVL006-T1003
Convalife (Shanghai) Co., Ltd.
Phase 1/2 Not yet recruiting